The decrease of NE veno-arterial difference is a directly assessable physiologic marker reflecting the effects of RDN with reduced renal NE release from sympathetic nerves. The current systematic follow-up at 3 and 6 months of our patients will allow the evaluation for a possible association of the pre-post ⌬NE RV-RA with the BP response.
Background: Ambulatory blood pressure monitoring (ABPM) is mandatory in every patient with uncontrolled hypertension. Nighttime blood pressure and non-dipping is associated with cardiovascular morbidity and mortality. Catheter-based renal sympathetic denervation (RD) in patients with resistant hypertension has been shown to reduce sympathetic drive and office blood pressure. The influence of RD on ambulatory blood pressure (ABPM) has not been studied in details. Methods: One-hundert patients with resistant hypertension undergoing catheter-based renal denervation were included in the study. Systolic and diastolic blood pressure (SBP/DBP) as well as ABPM (SBP/DBP average, SBP/DBP daytime, SBP/DBP nighttime, heart rate (HR) average) and dipping-pattern were analyzed prior to, and at 3 and 6 months follow-up. Results: RD reduced office SBP and DBP at 3 and 6 months by 22.9/8.1 mmHg and 26.6/9.3 mmHg (p for all Ͻ0.001), respectively. After 3 and 6 months 24-hour average SBP/DBP was reduced by 8.9/4.9 mmHg (pϭ0.019/0.025) and 11.9.5/6.9 mmHg (pϭ0.022/0.011), respectively. Average SBP/DBP were lowered at 3 and 6 months follow-up at daytime by 9.6/5.1 mmHg (pϭ0.010/0.001) and 12.1/8.1 mmHg (pϭ0.001/ 0.001) and at nighttime by 6.6/5.8 mmHg (pϭ0.003/0.005) and 11.3/4.7 mmHg (pϭ0.001/0.001), respectively. Renal denervation also reduced maximum SBP by Ϫ11.9 mmHg at 3 months and by Ϫ14.4 mmHg at 6 months follow-up (pϭ0.009 and 0.006) whereas maximum DBP was not changed. Conclusions: Beside significant reductions in office SBP and DBP, RD also reduced 24-hour average, daytime and nighttime SBP and DBP as well as maximum SBP after 3 and 6 months. Background: Catheter-based selective renal sympathetic denervation has emerged as a new therapeutic option for patients with resistant hypertension. Recent studies have shown that ablation of the renal sympathetic nerves using radiofrequency (RF) energy delivered from within the renal artery is safe and effective. The OneShot™ device (Covidien, Campbell, CA) is a balloon-based RF system using a mounted spiral electrode with a unique feature of irrigation of the vessel lumen during treatment. The non-compliant balloon is inflated under low pressure (1 atm) in the renal artery. The electrode delivers RF energy to ablate adjacent nerve bundles with a single 2-minute treatment.
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Methods:
The RHAS study was a single-center feasibility study performed at Mercy Hospital in Auckland, New Zealand. Eligible patients had an office systolic blood pressure (SBP) Ն160 mmHg (Ն150 if diabetic) despite a drug regimen that included two or more antihypertensive medications. Renal artery diameters were 4-7mm. The primary endpoint was the ability to insert the OneShot™ device into each renal artery and deliver RF energy. Secondary endpoints included office SBP at 6 months. Results: Nine patients were enrolled; baseline characteristics and outcomes are shown below. The technical success rate was 88.9%. One failure occurred in the first enrolled patient and was due to an incorrect software setting which inhibited delivery of RF energy. All remaining patients had both renal arteries treated with the OneShot™ device. The mean procedure time (device insertion to end of treatment) was 16 minutes. At 30 days, the mean office SBP was 155 Ϯ 19 mmHg, a change of Ϫ31 Ϯ 14 mmHg. Six-month results are pending.
Characteristic/Outcome
Mean ؎ SD or % (n/N) Change from baseline (mmHg) Ϫ6 Ϯ 10
Conclusions:
The RHAS trial demonstrated rapid delivery of RF energy for renal sympathetic denervation using the OneShot™ device with safe blood pressure reduction at 1 month. Six-month data will be available at time of presentation.
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Background: Catheter-based renal artery denervation therapy has emerged as a novel therapy in patients with resistant hypertension (HTN). Although initially performed with a single electrode radiofrequency (RF) catheter, recent advances in catheter designs are using multiple pre-specified electrode positions. This theoretically could improve the safety and efficacy of this treatment. We present the 3-month safety and efficacy data from the international multicenter EnligHTN I trial. Methods: Inclusion criteria include patients from 18-80 years of age with office systolic BP Ն160 mmHg (Ն150 for patients with Type 2 diabetes) on Ն 3 anti HTN agents (including a diuretic) and renal artery diameter Ն 4mm and length Ն 20mm. Patients with dual main renal arteries are excluded. The primary end-point is the change in office BP at 6 months from baseline. The safety endpoints include vascular and renal artery complications. Renal artery CT angiography is performed at baseline and repeated at 6 months. Utilizing femoral artery access with an 8Fr RDC guiding sheath the EnligHTN catheter is introduced into the renal artery, and RF energy delivered sequentially for 90 seconds per electrode. The catheter is repositioned, rotated and denervation repeated. Both renal arteries are treated. Results: In total 46 patients underwent renal denervation. Mean age was 60Ϯ10 yrs and baseline BP 176/96 mmHg. The median procedure time (from initiation to completion of RF delivery) was 34.0 min. The mean number of therapies delivered was 7.7 for the right and 7.4 for the left renal arteries. There was no change in renal function pre and post procedure (eGFR 76 and 75 mL/min/1.73m2 respectively). There were no renal artery or serious vascular complications through 3 months. The BP changes pre-discharge and at 1 month were Ϫ23/ 9(nϭ45, pϽ0.0001) and Ϫ28/10 mmHg respectively(nϭ46, pϽ0.0001). The preliminary 3-month BP change is Ϫ37/17 mmHg(nϭ24, pϽ0.0001). Conclusions: Renal denervation was performed safely and swiftly in patients with resistant HTN using the EnligHTN catheter. Initial results show a significant early reduction in BP that continues to reduce further at 3 months.
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